(CERS) Cerus - Ratings and Ratios

Cerus Corporation (NASDAQ:CERS) is a biomedical products company specializing in blood safety solutions. The companys core technology, the INTERCEPT Blood System, is a proprietary platform designed to enhance the safety of blood components by inactivating blood-borne pathogens. This system addresses a critical need in transfusion medicine by reducing the risk of transfusion-transmitted infections. The INTERCEPT Blood System is applicable across multiple blood components, including platelets, plasma, and red blood cells, ensuring a broader safety net for patients receiving blood transfusions.

The companys product portfolio includes systems for pathogen reduction in platelets, plasma, and red blood cells, as well as cryoprecipitated fibrinogen complex for treating bleeding disorders. Cerus markets its products through a combination of direct sales and distributor networks, with a global presence spanning the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international markets. The company was founded in 1991 and is headquartered in Concord, California.

Cerus Corporation operates in the health care supplies industry, with a market capitalization of approximately $302.72 million. The company trades on the NASDAQ exchange under the ticker symbol CERS. Its financial metrics include a price-to-sales ratio of 1.68 and a price-to-book ratio of 5.42, reflecting its current valuation. While the company has yet to achieve profitability, as indicated by a return on equity of -36.77, its focus on innovation and market expansion positions it as a key player in the blood safety sector.